New RA pill takes on tofacitinib in Head-to-Head trial

NCT ID NCT06020144

Ongoing Disease control Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofacitinib for 52 weeks, and researchers measure joint pain, swelling, and disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TLL-018 (oral tablet)
What this could lead to: If successful, TLL-018 could offer a new oral treatment option for people with rheumatoid arthritis who have not responded well to biologic drugs.
What could go wrong: This is a head-to-head comparison against an existing drug, so TLL-018 may not prove superior. As with any RA treatment, there are risks of infection and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.